David Alsteens (WELBIO - UCLouvain) and his team demonstrate the role of α-sialylated glycans in enhancing oncolytic therapy in breast cancer using atomic force microscopy.
Cédric Blanpain (WELBIO - ULB) is the 2022 winner of the EACR’s Mike Price Gold Medal, which rewards a senior researcher who has made an outstanding contribution to the progress of cancer research in Europe.
Alain Chariot (WELBIO – ULiège) and his team demonstrated that COP1 can act as an oncogenic E3 ligase by promoting ERa signaling but also as a tumor suppressor candidate by preventing epithelial-mesenchymal transition.
From fundamental research on bacterial metabolism in Abel Garcia-Pino's laboratory (WELBIO - ULB) to the development of a new generation of antibiotics.
The Ernest Solvay 2020 Prize of the Queen Elisabeth Medical Foundation was awarded to Benoît Vanhollebeke (WELBIO - ULB) at a ceremony attended by Her Majesty the Queen.
The FRFS-WELBIO announces its 2021 call for "WELBIO Investigator programmes" for basic research in the fields of life sciences that can lead to applications in all fields of (bio)technology.
Le Prix Joseph Maisin en Sciences biomédicales fondamentales 2020 a été attribué à Jean-François Collet (WELBIO - UCLouvain) lors d’une cérémonie en présence de Sa Majesté le Roi.
Abel Garcia-Pino (WELBIO – ULB) and his team shed light on the role played by alarmone for induction of the synthetic activity of E. coli RelA by starved ribosomes.
Abel Garcia-Pino (WELBIO – ULB) and his team uncovered the mechanism of toxicity used by the toxin-antitoxin systems (toxSAS) in bacteria.
2020 marks the 10th anniversary of our first call for projects! Learn about our researchers, their scientific advances and how some of their discoveries have been translated into applications for human health.
François Fuks (WELBIO – ULB) and his team demonstrated the role of the regulation of RNA epigenetics by the FTO enzyme in the development of cancer metastasis.
From disruptive research of scientific founder Benoit Vanhollebeke (WELBIO - ULB) to the development of blood-brain barrier pharmaceuticals aiming at repairing neurovascular function and neurodegenerative diseases.